Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

112.75 -0.69 (-0.61%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
News headline image
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Earnings Outlook For Incyte ↗
 
Via Benzinga
News headline image
2 Steady Stocks to Buy in a Recession ↗
Both companies are performing better than the broader market over the past year. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Golden Cross Appears Before Incyte Investors ↗
 
Via Benzinga
News headline image
Expert Ratings for Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers ↗
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock... 
Via Talk Markets
News headline image
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
From Incyte
Via Business Wire
News headline image
Why These 7 Healthcare Stocks Could Soar in 2023 ↗
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
News headline image
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion ↗
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by... 
Via Talk Markets
News headline image
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗
These two biotechs are flying high right now. 
Via The Motley Fool
News headline image
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
News headline image
Cramer Says He's 'Always Liked' This Drug Company ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower. 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients ↗
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX< 
Via Benzinga
News headline image
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
From Incyte
Via Business Wire
News headline image
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
From Incyte
Via Business Wire
News headline image
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
From Incyte and Mirati
Via Business Wire
News headline image
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Incyte
Via Business Wire
News headline image
7 Cash-Rich Stocks to Buy for Peace of Mind ↗
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven. 
Via InvestorPlace
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
News headline image
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Recap: Incyte Q3 Earnings ↗
Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by... 
Via Benzinga
News headline image
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
From Incyte
Via Business Wire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.